Literature DB >> 8039220

Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time.

J S Reiner1, K S Coyne, C F Lundergan, A M Ross.   

Abstract

Heparin anticoagulation is utilized during and after interventional cardiac catheterization procedures to reduce the risk of acute thrombotic coronary artery occlusion. The short half-life of heparin, the importance of maintaining therapeutic anticoagulation, and the time delay inherent in the processing and retrieval of the activated partial thromboplastin time (aPTT) by the hospital laboratory has generated interest in point-of-care heparin monitoring. The activated clotting time (ACT), the aPTT as assessed by both a new portable device, as well as the hospital laboratory, and heparin levels (H) were obtained from the same sample of blood in 100 patients receiving intravenous heparin. There was an excellent correlation between the aPTT determined at the bedside and by the hospital laboratory (r = .89). The ACT did not correlate well with either the laboratory or bedside aPTT (r = .63, .68 respectively). In the sub-therapeutic and therapeutic range, there was essentially no correlation between ACT and H. Only ACT values > 225 sec were predictive of therapeutic or supra-therapeutic aPTTs. ACT values < 225 sec, however, were not useful in predicting degree of anticoagulation. In situations in which the maintenance of therapeutic anticoagulation is critical as well as those in which the determination of lack of anticoagulation is required, the bedside determination of aPTT appears to be a useful tool.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039220     DOI: 10.1002/ccd.1810320112

Source DB:  PubMed          Journal:  Cathet Cardiovasc Diagn        ISSN: 0098-6569


  9 in total

Review 1.  The role of point-of-care anticoagulation monitoring in arterial and venous thromboembolic disorders.

Authors:  C R Zimmerman
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

2.  Bedside coagulometry during intravenous heparin therapy after coronary angioplasty.

Authors:  A P Schroeder; L L Knudsen; S E Husted; L Knudsen; J Ingerslev
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

3.  Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.

Authors:  R Kubalek; A Berlis; M Schwab; J Klisch; M Schumacher
Journal:  Neuroradiology       Date:  2003-03-28       Impact factor: 2.804

4.  Point of care management of heparin administration after heart surgery: A randomized, controlled trial.

Authors:  Paolo G Merlani; Catherine Chenaud; Silvia Cottini; Guido Reber; Philippe Garnerin; Philippe de Moerloose; Bara Ricou
Journal:  Intensive Care Med       Date:  2006-07-13       Impact factor: 17.440

5.  Safety and efficacy of fixed-dose heparin in carotid endarterectomy.

Authors:  A Poisik; E J Heyer; R A Solomon; D O Quest; D C Adams; C M Baldasserini; D J McMahon; J Huang; L J Kim; T F Choudhri; E S Connolly
Journal:  Neurosurgery       Date:  1999-09       Impact factor: 4.654

6.  The use of the activated clotting time for monitoring heparin therapy in critically ill patients.

Authors:  Jan J De Waele; Sebastiaan Van Cauwenberghe; Eric Hoste; Dominique Benoit; Francis Colardyn
Journal:  Intensive Care Med       Date:  2003-01-16       Impact factor: 17.440

7.  Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation.

Authors:  Jason P Sulkowski; Thomas J Preston; Jennifer N Cooper; Victoria L Duffy; Katherine J Deans; Louis G Chicoine; Peter C Minneci
Journal:  J Extra Corpor Technol       Date:  2014-03

8.  Anticoagulation Management during First Five Days of Infant-Pediatric Extracorporeal Life Support.

Authors:  Kirk R Bingham; Jeffrey B Riley; Gregory J Schears
Journal:  J Extra Corpor Technol       Date:  2018-03

9.  An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model.

Authors:  Zachary B K Berk; Aakash Shah; Wenji Sun; Bartley P Griffith; Zhongjun J Wu
Journal:  Artif Organs       Date:  2021-11-02       Impact factor: 3.094

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.